Functional Effect of Treatment of Glottic Insufficiency With Calcium Hydroxyapatite

Sponsor
University Hospital Ostrava (Other)
Overall Status
Completed
CT.gov ID
NCT02275130
Collaborator
(none)
25
1
1
45
0.6

Study Details

Study Description

Brief Summary

The voice is an indispensable source of human communication. Current time puts high demands on the quality of voice in most professions. Organic or functional changes of vocal cords associated with their insufficiency lead to a deterioration of voice quality, voice fatigue, hoarseness or breathing difficulties. This has adverse psychological, social and economic consequences for the patient, the employer and its surroundings. The injection techniques can be performed under general and local anaesthesia. The defined injectable substance is inserted directly in the vocal cords, which increases its volume and results in an almost immediate improvement of the voice quality. For injection can be used various materials, e.g. autologous fat, calcium hydroxyapatite, silicone, and others. Injection techniques are less invasive, associated with less perioperative morbidity. Operation can be also performed under local anaesthesia in selected patients, therefore is preferred for patients with multiple comorbidities and risk of general anaesthesia.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Calcium Hydroxyapatite
  • Device: Radiesse Voice (Calcium Hydroxyapatite)
N/A

Detailed Description

The causes of glottic insufficiency (vocal fold insufficiency) may be paresis (immobility) of one or both vocal folds (of iatrogenic aetiology after thyroid surgery, neck operations or ingrowth of malignant tumours of the chest or mediastinum, idiopathic after viral infections or central neuropathy) and atrophy (loss of mass) of the vocal cords, which particularly affect older patients. Surgical treatment of insufficiency is indicated for patients in whom conservative treatment is ineffective.

Surgical treatment of vocal fold insufficiency is carried out in two ways:
  • By thyroplasty type I, operations performed mostly under general anaesthesia, by the external access to the neck with the insertion of a silicone block through the thyroid cartilage into the space next to the vocal cords, which moves it medially.

  • Augmentation of the vocal cords, at which an insertion of an own (fat, cartilage, etc.) or a foreign (Gore-Tex, silicone, etc.) material laterally from the vocal cords can facilitate a change in the position of the vocal cords. In recent years, more and more so-called augmentation injection techniques are preferred.

While thyroplasty has been carried out in the Czech Republic for 10-15 years, the clinicians have had only limited experience with the injection techniques, which has been used for several years only and information about the functional results are still insufficient to date.

The working hypotheses

  • Augmentation of vocal folds with hydroxyapatite leads to significant improvements in subjective and objective parameters of voice

  • Augmentation of vocal folds with hydroxyapatite is a method comparable with other methods of treatment of glottic insufficiency (thyroplasty type 1, vocal folds augmentation with autologous fat)

  • Augmentation of vocal folds with hydroxyapatite can be performed under local anaesthesia The objective of the study is to determine the functional effect of augmented vocal folds with calcium hydroxyapatite ("Radiesse Voice") by comparing selected defined parameters preoperatively and postoperatively.

Other anticipated benefits of the study treatment include improving the quality of life of patients (improved voice quality, breathing, improve of mental state, preventing of social isolation and economic consequences). It will also lead to the introduction of new processes, materials and methods. It is also possible to expect shortening of the hospital stay, decrease in postoperative morbidity, and the possibility to perform the procedure on an outpatient basis.

The study has been designed as a prospective study, which is in conformity with the principles and guidelines of the Helsinki Declaration, good clinical practice and has been approved by the Ethical Committee of the University Hospital Ostrava.

The patients enrolled in the study will be followed for the period of twelve months.

Timetable of the study procedures and controls:
Preoperative examination:
  • Demographic data on age, sex, weight, height, smoking, cause of insufficiency

  • Questionnaires Voice Handicap Index (VHI)

  • Stroboscopy examination (assessment of the size of insufficiency)

  • Voice Analysis (Vospector Program - Breathable, Hoarseness, total grade of dysphonia, Maximum Phonation time, Dysphonia Severity Index - based on examination of the voice range

Examination 3 months postoperatively

  • Questionnaires Voice Handicap Index (VHI)

  • High-speed laryngoscopy, stroboscopy and videokymography (assessment of the size of insufficiency)

  • Voice Analysis (Vospector Program - Breathable, Hoarseness, total grade of dysphonia, Maximum Phonation time, Dysphonia Severity Index - based on examination of the voice range

Examination 6 months after surgery

  • Questionnaires Voice Handicap Index (VHI)

  • High-speed laryngoscopy, stroboscopy and videokymography (assessment of the size of insufficiency)

  • Voice Analysis (Vospector Program - Breathable, Hoarseness, total grade of dysphonia, Maximum Phonation time, Dysphonia Severity Index - based on examination of the voice range.

Examination 12 months after surgery (optional examination with cooperative patients)

  • Questionnaires Voice Handicap Index (VHI)

  • High-speed laryngoscopy, stroboscopy and videokymography (assessment of the size of insufficiency)

  • Voice Analysis (Vospector Program - Breathable, Hoarseness, total grade of dysphonia, Maximum Phonation time, Dysphonia Severity Index - based on examination of the voice range.

Statistical data processing For statistical evaluation descriptive statistics will be used (arithmetical average, standard deflection, frequency tables), X2 test, Fisher's exact test, analysis of variance (ANOVA), calculating of the OR (odds ratio) with 95 % confidence intervals, and logistic regression. Statistical tests will be evaluated at the significance level of 5%. Statistical analysis will be performed in the "Stata 10" programme. Program MS Excel will be used for data collection.

Study Design

Study Type:
Interventional
Actual Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Assessment of the Functional Effect of Treatment of Glottic Insufficiency With Injection Technique With the Use of Calcium Hydroxyapatite
Actual Study Start Date :
Apr 1, 2014
Actual Primary Completion Date :
Dec 1, 2017
Actual Study Completion Date :
Jan 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Calcium Hydroxyapatite

30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique

Procedure: Calcium Hydroxyapatite
Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
Other Names:
  • Radiesse Voice
  • Device: Radiesse Voice (Calcium Hydroxyapatite)

    Outcome Measures

    Primary Outcome Measures

    1. Objective improvement of voice parameters [32 months]

      irregularity, noise, overall severity, jitter, shimmer, GNE

    Secondary Outcome Measures

    1. Endoscopic assessment [32 months]

      The presence or absence of insufficiency (YES/NO) will be assessed prior to the surgical intervention and after the intervention, by the means of endoscopy examination

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 18-70 years

    • Insufficiency caused by paresis or atrophy

    • Duration of insufficiency of at least six months

    • Size of the insufficiency not exceeding three millimetres

    • Signing of the informed consent

    Exclusion Criteria:
    • Size of the insufficiency exceeding three millimetres

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Ostrava Ostrava Czech Republic Czechia 708 52

    Sponsors and Collaborators

    • University Hospital Ostrava

    Investigators

    • Principal Investigator: Radana Walderová, MD, University Hospital Ostrava

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital Ostrava
    ClinicalTrials.gov Identifier:
    NCT02275130
    Other Study ID Numbers:
    • FNO-ENT-Radiesse Voice
    • DRO-FNOs/2014
    First Posted:
    Oct 27, 2014
    Last Update Posted:
    Apr 5, 2018
    Last Verified:
    Apr 1, 2018
    Keywords provided by University Hospital Ostrava
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 5, 2018